Sam is a trader and one of our lead stock analysts at AskTraders. After starting his career predominantly in the forex markets, Sam now focuses on gold and stocks with a preference for macroeconomic analysis.
Shares of biotechnology company Destiny Pharma (LON: DEST) are making positive gains on Wednesday after the company announced Dr Stephanie Bewick's appointment as its new Chief Business Officer.
Dr Berwick brings a wealth of experience to the table with 20 years of experience in business development at public and private biotech companies and most recently served as Vice President, Business Development at Summit Therapeutics, a NASDAQ-listed infectious disease company.
“I am very pleased to welcome Stephanie to Destiny Pharma. She brings a wealth of experience and a proven track record in business development and deal-making having completed a range of transactions including in the anti-infectives space. Her expertise will be invaluable to Destiny Pharma,” commented Neil Clark, Chief Executive Officer of Destiny.
Dr Berwick said “Destiny Pharma has a fantastic XF platform and biotherapeutic/microbiome pipeline with unique late-stage clinical assets. I look forward to working with Neil and the team to progress the vibrant pipeline.”
Destiny’s share rose to highs of 86p, although they are now trading at 83.5p, up 12.42% on the day.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .